Skip to main content
Erschienen in: Annals of Hematology 9/2013

01.09.2013 | Original Article

Bendamustine salvage therapy for T cell neoplasms

verfasst von: Francesco Zaja, Luca Baldini, Andrés J. M. Ferreri, Stefano Luminari, Alberto Grossi, Flavia Salvi, Renato Zambello, Maria Goldaniga, Stefano Volpetti, Renato Fanin

Erschienen in: Annals of Hematology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3–4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1–18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.
Literatur
1.
Zurück zum Zitat The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89(11):3909–3918 The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89(11):3909–3918
2.
Zurück zum Zitat Dodero A, Spina F, Narni F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520–526PubMedCrossRef Dodero A, Spina F, Narni F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520–526PubMedCrossRef
3.
Zurück zum Zitat Hosing C, Champlin RE (2011) Stem-cell transplantation in T cell non-Hodgkin’s lymphomas. Ann Oncol 22(7):1471–1477PubMedCrossRef Hosing C, Champlin RE (2011) Stem-cell transplantation in T cell non-Hodgkin’s lymphomas. Ann Oncol 22(7):1471–1477PubMedCrossRef
4.
Zurück zum Zitat Knauf WU, Lissitchkov T, Aldaoud A et al (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67–77. doi:10.1111/bjh.12000, Epub 2012 Aug 4PubMedCrossRef Knauf WU, Lissitchkov T, Aldaoud A et al (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67–77. doi:10.​1111/​bjh.​12000, Epub 2012 Aug 4PubMedCrossRef
5.
Zurück zum Zitat Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29(26):3559–3566PubMedCrossRef Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29(26):3559–3566PubMedCrossRef
6.
Zurück zum Zitat Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209–3216. doi:10.1200/JCO.2011.39.2688, Epub 2012 Aug 6PubMedCrossRef Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209–3216. doi:10.​1200/​JCO.​2011.​39.​2688, Epub 2012 Aug 6PubMedCrossRef
7.
Zurück zum Zitat Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389PubMedCrossRef Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389PubMedCrossRef
8.
Zurück zum Zitat Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26(27):4473–4479PubMedCrossRef Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26(27):4473–4479PubMedCrossRef
9.
Zurück zum Zitat Ohmachi K, Ando K, Ogura M et al (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064PubMedCrossRef Ohmachi K, Ando K, Ogura M et al (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064PubMedCrossRef
10.
Zurück zum Zitat Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116(1):106–114PubMed Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116(1):106–114PubMed
11.
Zurück zum Zitat Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T cell lymphomas: the BENTLY trial. J Clin Oncol 31(1):104–10. doi:10.1200/JCO.2012.43.7285, Epub 2012 Oct 29PubMedCrossRef Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T cell lymphomas: the BENTLY trial. J Clin Oncol 31(1):104–10. doi:10.​1200/​JCO.​2012.​43.​7285, Epub 2012 Oct 29PubMedCrossRef
12.
Zurück zum Zitat Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMedCrossRef Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMedCrossRef
13.
Zurück zum Zitat Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598–2607PubMedCrossRef Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598–2607PubMedCrossRef
14.
Zurück zum Zitat Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196PubMedCrossRef Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196PubMedCrossRef
15.
Zurück zum Zitat O’Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189PubMedCrossRef O’Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189PubMedCrossRef
16.
Zurück zum Zitat Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J Clin Oncol 27(32):5410–5417PubMedCrossRef Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J Clin Oncol 27(32):5410–5417PubMedCrossRef
17.
Zurück zum Zitat Piekarz RL, Frye R, Prince HM et al (2011) Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117(22):5827–5834PubMedCrossRef Piekarz RL, Frye R, Prince HM et al (2011) Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117(22):5827–5834PubMedCrossRef
18.
Zurück zum Zitat Coiffier B, Pro B, Prince HM et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631–636PubMedCrossRef Coiffier B, Pro B, Prince HM et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631–636PubMedCrossRef
19.
Zurück zum Zitat Dueck G, Chua N, Prasad A et al (2010) Interim report of a phase 2 clinical trial of lenalidomide for T cell non-Hodgkin lymphoma. Cancer 116:4541–4548PubMedCrossRef Dueck G, Chua N, Prasad A et al (2010) Interim report of a phase 2 clinical trial of lenalidomide for T cell non-Hodgkin lymphoma. Cancer 116:4541–4548PubMedCrossRef
20.
Zurück zum Zitat Friedberg J, Mahadevan D, Jung JA et al (2011) Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B an T cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 118(46):Abs95 Friedberg J, Mahadevan D, Jung JA et al (2011) Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B an T cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 118(46):Abs95
Metadaten
Titel
Bendamustine salvage therapy for T cell neoplasms
verfasst von
Francesco Zaja
Luca Baldini
Andrés J. M. Ferreri
Stefano Luminari
Alberto Grossi
Flavia Salvi
Renato Zambello
Maria Goldaniga
Stefano Volpetti
Renato Fanin
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1746-9

Weitere Artikel der Ausgabe 9/2013

Annals of Hematology 9/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.